What are the recommended dosing regimens for amphetamine (immediate‑release and extended‑release) in adults, children, and for narcolepsy, and what monitoring and contraindications should be considered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amphetamine Dosing Recommendations

Immediate-Release Amphetamine Dosing

For ADHD in children and adolescents, start with 2.5 mg daily for ages 3-5 years or 5 mg once or twice daily for ages 6 and older, titrating by 2.5-5 mg weekly until optimal response is achieved, with a maximum of 40 mg/day. 1

Pediatric ADHD Dosing Algorithm

Ages 3-5 years:

  • Starting dose: 2.5 mg daily
  • Titration: Increase by 2.5 mg weekly
  • Maximum: 40 mg/day (rarely needed)
  • Timing: First dose upon awakening, additional doses at 4-6 hour intervals 1

Ages 6 years and older:

  • Starting dose: 5 mg once or twice daily
  • Titration: Increase by 5 mg weekly 2, 1
  • Maximum: 40 mg/day total daily dose 2, 1
  • Single dose limit: 10 mg for children <25 kg 2
  • Timing: First dose upon awakening, additional doses (1-2) at 4-6 hour intervals 1

Adult ADHD Dosing

For adults with ADHD, extended-release amphetamine formulations at 20-60 mg/day are effective, with most patients achieving optimal response at 40-60 mg/day. 3

The landmark adult ADHD trial demonstrated that doses of 20,40, and 60 mg/day all produced statistically significant improvements, with effect sizes of 0.8. Notably, adults with severe symptoms (ADHD Rating Scale >32) showed greater benefit at the highest dose of 60 mg/day 3. This contrasts with community practice patterns where dosing tends to be lower than clinical trial doses 4.

Narcolepsy Dosing

For narcolepsy, start with 5 mg daily in children ages 6-12 years or 10 mg daily in patients ≥12 years, titrating by 5-10 mg weekly to a usual range of 5-60 mg/day in divided doses. 1

Specific narcolepsy protocol:

  • Ages 6-12 years: Start 5 mg daily, increase by 5 mg weekly
  • Ages ≥12 years: Start 10 mg daily, increase by 10 mg weekly
  • Usual effective range: 5-60 mg/day 1
  • Timing: First dose upon awakening, additional doses at 4-6 hour intervals 1

Research demonstrates that methamphetamine 40-60 mg daily allowed narcoleptics to function at levels comparable to unmedicated controls, with mean sleep latency improving from 4.3 to 9.3 minutes 5. Dextroamphetamine 30 mg daily roughly halved narcolepsy attack frequency 6.

Extended-Release Amphetamine Dosing

Extended-release amphetamine formulations provide 12-hour symptom control and should be initiated at 20 mg daily in adults, with most patients stabilizing at 40-60 mg/day. 3

Key Advantages of Extended-Release Formulations

  • Duration of action: Significant improvements at both 4 and 12 hours post-dose 3
  • Reduced supplementation needs: Dyanavel XR specifically reduces the need for immediate-release supplementation compared to other extended-release preparations 7
  • Simplified regimens: Once-daily dosing improves adherence 8

Titration Strategy: Fixed vs. Flexible Dosing

The most recent meta-analysis (2022) demonstrates that flexible-dose titration strategies produce superior outcomes compared to fixed-dose approaches. 9

Critical findings from this analysis:

  • Flexible-dose trials: Increased efficacy AND reduced discontinuations with higher doses across the entire FDA-licensed range
  • Fixed-dose trials: Incremental benefits plateaued beyond 30 mg MPH-equivalent (approximately 20 mg amphetamine)
  • Clinical implication: Titrate based on symptom control and tolerability rather than stopping at arbitrary dose limits 9

This evidence directly challenges the common practice of underdosing stimulants in clinical settings 4.

Monitoring Requirements

Obtain baseline blood pressure, pulse, height, and weight before initiating treatment. 2

Ongoing Monitoring Schedule

Children/adolescents:

  • Vital signs: Annually during routine physical examination
  • Weight: At each visit to objectively assess appetite effects 2

Adults:

  • Blood pressure and pulse: Quarterly 2

Systematic Assessment of Treatment Response

Evaluate target ADHD symptoms regularly from both parents and teachers (or self-report in adolescents/adults), supplemented by standardized rating scales. 2

Common side effects to assess systematically:

  • Insomnia
  • Anorexia/weight loss
  • Headaches
  • Social withdrawal
  • Tics 2

If bothersome adverse reactions appear (insomnia, anorexia), reduce the dose 1.

Contraindications and Critical Warnings

Avoid late evening doses due to insomnia risk. 1

Discover patients with:

  • Malignant hypertension (children/adolescents)
  • Essential hypertension (adults)
  • Cardiac arrhythmias 2

These conditions require careful evaluation before initiating stimulant therapy.

Practical Titration Approach

The optimal titration schedule involves weekly dose increases of 2.5-5 mg for amphetamine until symptom control is achieved or dose-limiting adverse events occur. 2

Alternative Fixed-Dose Trial Method

Consider a systematic trial of multiple doses (similar to the MTA study design) where different doses are tested weekly, then the optimal dose is selected based on comprehensive assessment. This approach ensures patients don't miss a higher dose that might yield additional improvement 2.

When to Stop Increasing Dose

If the top recommended dose doesn't help, more is not necessarily better—consider changing medications or adding environmental/psychosocial interventions. 2

However, the 2022 meta-analysis suggests that in flexible-dose scenarios, benefits continue across the full FDA-licensed range when titration is guided by clinical response 9.

Common Pitfalls

  1. Underdosing: Community practice consistently uses lower doses than clinical trials, potentially limiting treatment effectiveness 4

  2. Premature dose ceiling: Stopping titration at arbitrary limits rather than continuing to optimal response within FDA-approved ranges 9

  3. Inadequate monitoring frequency: Lower initial doses combined with three or more visits during the first 90 days are associated with appropriate dose titration 4

  4. Ignoring formulation differences: Extended-release formulations have longer half-lives and greater effects on appetite and sleep compared to immediate-release 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.